Reply to Comment on: High N-Terminal Pro-B-Type Natriuretic Peptide Levels Are Associated With Lower Physical Function Independent of Sarcopenia in Community-Dwelling Older Adults: The Shizuoka Study.
N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is back in the spotlight, thanks to a new exchange in Geriatrics & Gerontology International. Researchers from Japan doubled down on findings from the Shizuoka Study: higher NT-proBNP levels track with lower physical function in older adults, no matter their muscle mass status. The study’s reply tackles questions about what this biomarker is really telling us.
Geriatr Gerontol Int
by Kato M, Tanaka Y, Adachi T et al.
“Reply to Comment on: High N-Terminal Pro-B-Type Natriuretic Peptide Levels Are Associated With Lower Physical Function Independent of Sarcopenia in Community-Dwelling Older Adults: The Shizuoka Study. Kato M(1), Tanaka Y(2), Adachi T(1), Kito K(3), Nakano W(3), Nakano S(3), Kurita Y(3), Miyoshi K(3), Kushida O(4), Ozaki E(2), Kuriyama N(2), Tabara Y(2)(5). Author information: (1)Major in Rehabilitation Science, Department of Health Sciences, Nagoya City University Medical School, Nagoya, Japan. (2)Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan. (3)Department of Shizuoka Physical Therapy, Faculty of Health Science, Tokoha University, Shizuoka, Japan. (4)School of Food and Nutritional Sciences, University of Shizuoka, Shizuoka, Japan. (5)Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.”
Here’s the main point: NT-proBNP is more than just a heart marker. The Shizuoka team confirms that even when researchers factor out sarcopenia (age-related muscle loss), elevated NT-proBNP still flags people with lower physical performance. That means this peptide’s role stretches beyond traditional cardiac research.
Why does this matter for peptide researchers?
NT-proBNP is a workhorse in cardiac research, but now it’s proving useful in aging and physical function studies
Researchers can use NT-proBNP levels to identify at-risk populations, even before muscle loss sets in
Highlights how peptides can serve as early indicators for broader health issues, not just single diseases
The authors also stress the importance of careful design in peptide research. They call for more work controlling for confounders — like nutrition, comorbidities, and lifestyle — when interpreting NT-proBNP data. This is a good reminder for anyone running peptide biomarker studies or exploring new peptide endpoints.
Key takeaway: Peptides like NT-proBNP are gold mines for research, with applications reaching far past their original purpose. For the latest studies and peptide discoveries, browse the peptide research index.
Stay tuned — the field is moving fast, and peptides keep turning up in unexpected places.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.